摘要
目的探讨益生菌联合美沙拉嗪治疗对溃疡性结肠炎(UC)患者白细胞介素(IL)-23/IL-17炎症轴的影响。方法选取100例UC患者,随机分为观察组(n=50)和对照组(n=50)。对照组给予美沙拉嗪治疗,观察组给予益生菌联合美沙拉嗪,连续治疗8周。比较两组患者临床疗效、血清炎性因子(IL-23、IL-17)表达、复发率及不良反应。结果治疗后,观察组血清IL-23、IL-17水平分别为(407.2±93.4)、(256.3±32.4)pg/mL,对照组分别为(589.3±86.2)、(341.6±45.3)pg/mL,观察组显著低于对照组,差异有统计学意义(P<0.05)。观察组和对照组治疗有效率分别为94.0%(47/50)、80.0%(40/50),观察组临床疗效显著优于对照组,差异有统计学意义(P<0.05)。观察组和对照组复发率分别为4.2%(1/24)、26.3%(5/19),观察组显著低于对照组,差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论益生菌联合美沙拉嗪治疗UC,可显著提高临床疗效,而调节IL-23/IL-17炎症轴可能是其作用机制。
Objective To evaluate the efficacy of probiotics combined with mesalazine treatment on IL-23/IL-17 inflammatory axis in patients with ulcerative colitis （UC）.Methods A total of 100 patients with UC were divided into observation group （n=50） and control group （n=50）.The probiotics combined with mesalazine were used in observation group and mesalazine was used in control group,the treatment lasted for 8 weeks.The clinical efficacy,serum inflammatory factor （IL-23 and IL-17） expression,recurrence rate and adverse reaction were compared between the two groups.Results After treatment,the serum IL-23 and IL-17 levels of observation group were （407.2±93.4） and （256.3±32.4） pg/mL respectively,and which of control group respectively were （589.3±86.2） and （341.6±45.3） pg/mL.Differences were statistically significant （P〈0.05）.The clinical efficacy of observation group [94.0%（47/50）] was significantly higher than that of the control group [80.0%（40/50）].The recurrence rate of observation group[4.2%（1/24）] was significantly lower than that of the control group [26.3%（5/19）],the recurrence rate of observation group was significantly lower than control group （P〈0.05）.Adverse reactions were not severed in two groups.Conclusion Using probiotics combined with the mesalazine treatment on patients with UC,could significantly improve the clinical curative effect,and adjusting the IL-23/IL-17 expression may be its mechanism.
出处
《检验医学与临床》
CAS
2017年第10期1434-1435,1438,共3页
Laboratory Medicine and Clinic
